Completed PHASE2/PHASE3 INTERVENTIONAL 3-arm NCT00328653

Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)

Phase II/III, Multicenter, Double-Masked, Randomized, Parallel Group, Dose Ranging, Controlled Trial of Efficacy and Tolerance of Nova22007 (Cyclosporine A [CSA] 0.05% & 0.1% Ophthalmic Cationic Emulsion) Versus Vehicle in Patients With VKC

Sponsor: Santen SAS

Conditions Conjunctivitis, Vernal

Interventions Cyclosporine NOVA22007 0.05% Cyclosporine NOVA22007 0.1% Vehicle

Updated 6 times since 2017 Last updated: Nov 12, 2021 Started: May 31, 2006 Primary completion: Feb 22, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Conjunctivitis, Vernal and is currently completed. Santen SAS leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2022 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jan 2021 — Jan 2022 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

May 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Santen SAS

Data source: Santen SAS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Paris, France